非小细胞肺癌生存者的生活质量——一项多中心横断面研究
该多中心横断面研究纳入657例诊断后生存≥1年的NSCLC患者,中位诊断后时间3.7年,采用EORTC QLQ-C30及QLQ-LC13评估生活质量并与年龄性别标化一般人群比较。结果显示生存者几乎在所有领域存在临床意义的生活质量损害,全球QoL差10分(p<0.001),心理困扰是与各主要QoL量表较差相关的主要因素,较高体力活动与较好QoL相关。
要点
- NSCLC生存者较一般人群全球QoL差10分(p<0.001),当前治疗者损害16.0,无治疗≥12个月者8.3。
- 呼吸困难损害最大(41分),其次角色功能33分、疲乏27分、社会功能27分、躯体功能24分、失眠21分。
- 心理困扰与所有主要QoL量表较差相关(β|19-31|,均p<0.001),较高体力活动与较好QoL相关(β|10-20|,p<0.001)。
核心结论
- 肺癌生存者在积极治疗结束后仍长期存在功能受限和症状,支持提供长期支持性照护的重要性。
研究设计与样本
- 多中心横断面研究,纳入诊断后生存≥1年的NSCLC患者657例,中位诊断后时间3.7年(范围1.0-21.2年)。
- 采用EORTC QLQ-C30及QLQ-LC13评估生活质量,并与年龄和性别标化的一般人群参考值比较。
- 采用多变量线性回归分析患者、肿瘤和治疗相关因素与6个主要QoL量表的关联。
主要发现
- 与年龄性别标化一般人群相比,几乎在所有领域存在有临床意义的生活质量损害,全球QoL差10分(p<0.001)。
- 无治疗≥12个月患者全球QoL损害为8.3,当前治疗患者为16.0。
- 各亚组中损害最大的为呼吸困难41分、角色功能33分、疲乏27分、社会功能27分、躯体功能24分、失眠21分。
- 心理困扰与所有主要QoL量表较差相关(β|19-31|,均p<0.001)。
- 当前治疗(β|8-12|,p<0.01)、呼吸系统合并症(β|4-5|,p<0.01)和领取残疾养老金(β|10-11|,p<0.01)与多个主要QoL量表损害相关;较高体力活动(β|10-20|,p<0.001)和高收入(β|10-14|,p<0.01)与较好QoL相关。
临床怎么用
- 原文结论认为应重视提供长期支持性照护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The objective was to assess quality of life (QoL) in lung cancer survivors, compare it to the general population, and identify factors associated with global QoL, physical functioning, emotional functioning, fatigue, pain, and dyspnea. METHODS: Data from NSCLC patients who had survived 1 year or longer after diagnosis were collected cross-sectionally in a multicenter study. QoL was assessed with the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module QLQ-LC13 across different clinical subgroups and compared to age- and sex-standardized general population reference values. Multivariable linear regression analyses were performed to test the associations of patient-, tumor-, and treatment-related factors with the six primary QoL scales. RESULTS: Six hundred fifty-seven NSCLC patients participated in the study with a median time since diagnosis of 3.7 years (range, 1.0-21.2 years). Compared to the age- and sex-standardized general population, clinically meaningful differences in the QoL detriment were found on almost all domains: lung cancer survivors had clinically relevant poorer global QoL (10 points, p < 0.001). Whereas in 12 months or longer treatment-free patients this detriment was small (8.3), it was higher in patients currently in treatment (16.0). Regarding functioning and symptom scales, respective detriments were largest for dyspnea (41 points), role function (33 points), fatigue (27 points), social function (27 points), physical function (24 points), and insomnia (21 points) observed across all subgroups. The main factor associated with poorer QoL in all primary QoL scales was mental distress (β |19-31|, all p < 0.001). Detriments in QoL across multiple primary QoL scales were also observed with current treatment (β |8-12|, p < 0.01), respiratory comorbidity (β |4-5|, p < 0.01), and living on a disability pension (β |10-11|, p < 0.01). The main factor associated with better QoL in almost all primary QoL scales was higher physical activity (β |10-20|, p < 0.001). Better QoL was also observed in patients with high income (β |10-14|, p < 0.01). CONCLUSIONS: Lung cancer survivors experience both functional restrictions and symptoms that persist long term after active treatment ends. This substantiates the importance of providing long-term supportive care.
引用
- Hechtner M, Eichler M, Wehler B, et al. Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study. J Thorac Oncol. 2018. PMID: 30508641. doi:10.1016/j.jtho.2018.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。